by Sue Robbins | Mar 9, 2020 | Migraine
The Food and Drug Administration (FDA) has approved Nurtec™ ODT (rimegepant; Biohaven) for the acute treatment of migraine with or without aura in adults. Nurtec ODT is a calcitonin gene-related peptide receptor antagonist administered via an orally disintegrating...
by Sue Robbins | Mar 9, 2020 | Migraine
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Qtrypta™ (M207) (zolmitriptan intracutaneous microneedle system; Zosano Pharma) for the acute treatment of migraine. Qtrypta delivers zolmitriptan, a selective...
by Sue Robbins | Mar 5, 2020 | Migraine
If you have raging headaches and you spend a lot of time on your smartphone, a new study suggests you might want to put your phone down whenever you can. Researchers found that folks who use their smartphones frequently and have headaches or migraines also tend to...
by Sue Robbins | Feb 28, 2020 | Migraine
NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved Nurtec ODT (rimegepant) for the acute treatment of migraine in adults. Nurtec...
by Sue Robbins | Feb 25, 2020 | Migraine
The United States Food and Drug Administration (US FDA) has just approved Vyepti™ for the preventive treatment of migraine. Vyepti (eptinezumab-jjmr) will be the first intravenous (IV) preventive treatment on the market for migraine disease. It will be available...
